Contents 3 min read

Claim and source comparison

ALCAR: an Alzheimer trial, two cognitive reviews, taxane neuropathy and the NIH carnitine safety summary.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Human randomized controlled trial

Spagnoli et al. (1991) conducted a one-year placebo-controlled ALCAR trial in 130 people with Alzheimer's disease. Both groups declined, with slower deterioration on some tests in the ALCAR group.

Selected differences across multiple tests do not show that disease stopped or memory improved in healthy people. Read the result alongside later reviews.

Source 1 · Abstract read

Systematic review / meta-analysis

Montgomery et al. (2003) pooled trials lasting 3–12 months in mild cognitive impairment or mild Alzheimer's disease. The integrated clinical and psychometric outcome showed a small difference favoring ALCAR over placebo (effect size 0.201).

This older analysis pooling different scales does not establish cognitive benefit in healthy young people or routine dementia treatment. The Cochrane assessment is more cautious.

Source 2 · Abstract read

Systematic review / meta-analysis

Across 16 trials in the Cochrane review, some 24-week measures were positive, but benefit was not shown for dementia severity or functional ability. Positive findings may reflect multiple comparisons; routine clinical use was not recommended.

Populations and measures in this older review were heterogeneous; most analyses used trial completers. The findings are not a complete assessment of newer research or use in healthy people.

Source 9 · Official summary read

Human randomized controlled trial

In a trial evaluating 409 women with breast cancer receiving taxanes, 3 g/day ALCAR did not prevent neuropathy at week 12; neuropathy was worse at week 24. Follow-up analysis also reported an adverse difference over two years.

This result concerns taxane chemotherapy and the studied ALCAR regimen; neuropathy types are not equivalent. It provides no basis for self-use to prevent neuropathy during chemotherapy.

Source 6 · Source 7 · Abstract read

Official safety summary

NIH ODS notes that carnitine supplements can cause nausea, diarrhea and fishy body odor. A tolerable upper intake level has not been established for carnitine.

This carnitine-family summary does not determine ALCAR-specific adverse-effect rates or the magnitude of drug interactions. Absence of an upper limit does not mean unlimited safety.

Source 8 · Official summary read

Our evidence and source methodology

Acetyl-L-Carnitine: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Acetyl-L-Carnitine?

Acetyl-L-carnitine plays a role in energy metabolism. Cognitive and neuropathy research findings vary by condition; cognitive benefits in healthy young people remain uncertain.

Mechanism of Effect

Most mechanism findings in this section come from cell or animal experiments; they do not establish the same effects or clinical benefits in humans.

Clinical Evidence

Spagnoli et al. (1991) conducted a one-year placebo-controlled ALCAR trial in 130 people with Alzheimer's disease. Both groups declined, with slower deterioration on some tests in the ALCAR group.

Selected differences across multiple tests do not show that disease stopped or memory improved in healthy people. Read the result alongside later reviews.

Montgomery et al. (2003) pooled trials lasting 3–12 months in mild cognitive impairment or mild Alzheimer's disease. The integrated clinical and psychometric outcome showed a small difference favoring ALCAR over placebo (effect size 0.201).

This older analysis pooling different scales does not establish cognitive benefit in healthy young people or routine dementia treatment. The Cochrane assessment is more cautious.

Across 16 trials in the Cochrane review, some 24-week measures were positive, but benefit was not shown for dementia severity or functional ability. Positive findings may reflect multiple comparisons; routine clinical use was not recommended.

Populations and measures in this older review were heterogeneous; most analyses used trial completers. The findings are not a complete assessment of newer research or use in healthy people.

Di Stefano et al. (2019) systematically reviewed ALCAR research in painful peripheral neuropathy; this publication is not a randomized trial from 2000. Results cannot be treated as equivalent across different neuropathy causes.

Dose information and research limits

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

This comparison did not identify a suitable human plasma measurement validating the profile's general half-life; no numeric duration is used by the tool.

Controlled studies have not adequately established the efficacy and safety of these combinations in healthy people. Theoretical complementarity is not proven synergy or a recommendation to combine them.

Safety and Side Effects

In a trial evaluating 409 women with breast cancer receiving taxanes, 3 g/day ALCAR did not prevent neuropathy at week 12; neuropathy was worse at week 24. Follow-up analysis also reported an adverse difference over two years.

This result concerns taxane chemotherapy and the studied ALCAR regimen; neuropathy types are not equivalent. It provides no basis for self-use to prevent neuropathy during chemotherapy.

In breast cancer patients receiving taxane chemotherapy, ALCAR did not prevent neuropathy and was associated with worse neuropathy in a randomized trial; the adverse difference persisted in long follow-up. Do not self-use it to prevent chemotherapy neuropathy; consult the oncology team.

NIH ODS notes that carnitine supplements can cause nausea, diarrhea and fishy body odor. A tolerable upper intake level has not been established for carnitine.

This carnitine-family summary does not determine ALCAR-specific adverse-effect rates or the magnitude of drug interactions. Absence of an upper limit does not mean unlimited safety.

Sources

  1. Spagnoli A, et al. (1991). Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology, 41(11), 1726–1732. PubMed · PMID 1944900
  2. Montgomery SA, et al. (2003). Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. International Clinical Psychopharmacology, 18(2), 61–71. PubMed · PMID 12598816
  3. Ames BN, et al. (2004). Delaying the mitochondrial decay of aging with acetylcarnitine. Annals of the New York Academy of Sciences, 1033, 108–116. PubMed · PMID 15591008
  4. Di Stefano G, et al. (2019). Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review. Journal of Pain Research, 12, 1341–1351. https://doi.org/10.2147/JPR.S190231 PubMed · PMID 31118753
  5. Bianchetti A, et al. (2003). Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Current Medical Research and Opinion, 19(4), 350–353. PubMed · PMID 12841930
  6. Hershman DL, et al. (2013). Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. Journal of Clinical Oncology, 31(20), 2627–33. https://doi.org/10.1200/JCO.2012.44.8738 PubMed · PMID 23733756
  7. Hershman DL, et al. (2018). Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). Journal of the National Cancer Institute, 110(6), 669–676. https://doi.org/10.1093/jnci/djx259 PubMed · PMID 29361042
  8. National Institutes of Health, Office of Dietary Supplements. Carnitine: Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/carnitine-healthprofessional/ NIH Office of Dietary Supplements
  9. Hudson SA, Tabet N. (2003). Acetyl-L-carnitine for dementia. Cochrane Database of Systematic Reviews, (2), CD003158. PubMed · PMID 12804452

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions